ArticleBioengineering (Basel, Switzerland)2024
CardioRiskNet: A Hybrid AI-Based Model for Explainable Risk Prediction and Prognosis in Cardiovascular Disease.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Foundation models for cardiovascular diseases and medicine.European heart journal. Digital health · 2026Review
- Improving airport security with IoT-powered deep learning methods for threat detection and intelligent recommendation systems.Scientific reports · 2026Article
- Artificial Intelligence in African Cardiovascular Care: Opportunities, Challenges, and Pathways to Improved Outcomes.Public health challenges · 2026Review
- FibroidX: Vision Transformer-Powered Prognosis and Recurrence Prediction for Uterine Fibroids Using Ultrasound Images.Cancers · 2026Article
- Sustainable and interpretable heart disease prediction: a clinical decision support approach for biomedical healthcare applications.Scientific reports · 2026Article
- An explainable machine learning framework for cardiovascular risk prediction using structured health data.Frontiers in artificial intelligence · 2026Article
- Artificial Intelligence-Assisted Nanosensors for Clinical Diagnostics: Current Advances and Future Prospects.Biosensors · 2025Review
- Enhanced machine learning and hybrid ensemble approaches for Coronary Heart Disease prediction.PloS one · 2025Article
- Predictive value of heart rate for prognosis in patients with cerebral infarction without atrial fibrillation comorbidity analyzed according to the MIMIC-IV database.Frontiers in neurology · 2025Article
- A comprehensive review of machine learning for heart disease prediction: challenges, trends, ethical considerations, and future directions.Frontiers in artificial intelligence · 2025Review
- XAI-Augmented Voting Ensemble Models for Heart Disease Prediction: A SHAP and LIME-Based Approach.Bioengineering (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of cardiovascular diseases (CVDs) as a leading cause of death highlights the imperative need for refined risk assessment and prognostication methods. The traditional approaches, including the Framingham Risk Score, blood tests, imaging techniques, and clinical assessments, although widely utilized, are hindered by limitations such as a lack of precision, the reliance on static risk variables, and the inability to adapt to new patient data, thereby necessitating the exploration of alternative strategies. In response, this study introduces CardioRiskNet, a hybrid AI-based model designed to transcend these limitations. The proposed CardioRiskNet consists of seven parts: data preprocessing, feature selection and encoding, eXplainable AI (XAI) integration, active learning, attention mechanisms, risk prediction and prognosis, evaluation and validation, and deployment and integration. At first, the patient data are preprocessed by cleaning the data, handling the missing values, applying a normalization process, and extracting the features. Next, the most informative features are selected and the categorical variables are converted into a numerical form. Distinctively, CardioRiskNet employs active learning to iteratively select informative samples, enhancing its learning efficacy, while its attention mechanism dynamically focuses on the relevant features for precise risk prediction. Additionally, the integration of XAI facilitates interpretability and transparency in the decision-making processes. According to the experimental results, CardioRiskNet demonstrates superior performance in terms of accuracy, sensitivity, specificity, and F1-Score, with values of 98.7%, 98.7%, 99%, and 98.7%, respectively. These findings show that CardioRiskNet can accurately assess and prognosticate the CVD risk, demonstrating the power of active learning and AI to surpass the conventional methods. Thus, CardioRiskNet's novel approach and high performance advance the management of CVDs and provide healthcare professionals a powerful tool for patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.